Letter: tenofovir may be superior to entecavir for treatment-naive chronic hepatitis B patients

被引：2
|
作者：
Wang, Ji-Gan [1 ]
Chen, Rui [1 ]
Wang, Li-Chuan [1 ]
机构：
[1] Maternal & Child Hlth Hosp Guangxi Zhuang Autonom, Nanning, Peoples R China
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2021年 / 53卷 / 09期
关键词：
HEPATOCELLULAR-CARCINOMA; VIRAL LOAD; MORTALITY; RISK; HBV;
D O I：
10.1111/apt.16323
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1048 / 1049
页数：2
相关论文
共 50 条
  • [41] Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B
    Fahrtash-Bahin, Farzan
    Kariyawasam, Viraj C.
    Gray, Timothy
    Byth, Karen
    George, Jacob
    Douglas, Mark W.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (05) : 721 - 726
  • [42] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E898 - E904
  • [43] Potential antiviral drug resistance mutations in patients with treatment-naive chronic hepatitis B
    Cakal, Bulent
    Cavus, Bilger
    Poda, Mehves
    Atasoy, Alp
    Bulakci, Mesut
    Gulluoglu, Mine
    Akyuz, Filiz
    ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2024, 15 (03): : 182 - 187
  • [44] Lower risk of hepatocellular carcinoma with tenofovir than entecavir in antiviral treatment-naive chronic hepatitis B patients: a systematic review and meta-analysis involving 90,897 participants
    Shao, Jinman
    Wang, Yishu
    Hu, Ling
    Zhang, Lianchao
    Lyu, Chunmei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2131 - 2140
  • [45] Entecavir for the long-term treatment of chronic hepatitis B
    Gonzalez, Stevan A.
    Keeffe, Emmet B.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (09) : 1053 - 1062
  • [46] Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience
    Tarsetti, Fabio
    Tarantino, Giuseppe
    Mosca, Piergiorgio
    Scarpellini, Emidio
    Fava, Giammarco
    CLINICAL MANAGEMENT ISSUES, 2015, 9 (04) : 95 - 100
  • [47] Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment
    Tao, Ya-Chao
    Wang, Meng-Lan
    Zhang, Dong-Mei
    Wu, Dong-Bo
    Wang, Yong-Hong
    Liao, Juan
    Tang, Hong
    Chen, En-Qiang
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (07) : 731 - 738
  • [48] Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir
    Sato, Kosuke
    Inoue, Jun
    Akahane, Takehiro
    Kobayashi, Tomoo
    Takai, Satoshi
    Nakamura, Takuya
    Sato, Toshihiro
    Kimura, Osamu
    Ninomiya, Masashi
    Iwata, Tomoaki
    Sano, Akitoshi
    Tsuruoka, Mio
    Onuki, Masazumi
    Sawahashi, Satoko
    Niitsuma, Hirofumi
    Masamune, Atsushi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 258 (04) : 277 - 285
  • [49] Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naive patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma
    Wang, Meirong
    Qiu, Ning
    Lu, Shichun
    Xiu, Dianrong
    Yu, Jianguo
    Wang, Xing Tai
    Lu, Fengmin
    Li, Tong
    Liu, Xueen
    Zhuang, Hui
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (02) : 219 - 227
  • [50] Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
    Song, Yu-Xuan
    Song, Guang-Jun
    Ma, Hui
    Feng, Bo
    Xie, Yan-Di
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2025, 85 (01) : 64 - 72
12345